Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (NasdaqGS:INCY) from Outperform to Market Perform. Analyst Price Forecast Suggests 28.39% Upside As of March 4, ...

Fintel reports that on March 17, 2025, William Blair upgraded their outlook for DocuSign (NasdaqGS:DOCU) from Market Perform ...

Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients ...

Analysts at William Blair raised their Q1 2025 EPS estimates for Nektar Therapeutics in a research report issued to clients and investors on Thursday, March 13th. William Blair analyst A. Hsieh now ...

William Blair recommends that investors use the weakness this morning in Affrim (AFRM) to accumulate shares following news that ...

JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...

Investment firm William Blair has upgraded its rating on Palantir (PLTR) from Underperform to Market Perform due to the AI ...

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...

The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.

Palantir (PLTR) was upgraded to Market Perform from Underperform by William Blair, following the recent share price decline ...

We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...

We recently published a list of 11 Best Reddit Stocks to Invest In. In this article, we are going to take a look at where ...